TCR-mimic bispecific nanobody-based T cell engager targeting intracellular tumor antigens for cancer immunotherapy

A new immunotherapy platform successfully shrank tumors and prolonged survival in animal models without causing treatment-related harm.

What the study was

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.